Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02572336
Recruitment Status : Unknown
Verified October 2015 by D-Pharm Ltd..
Recruitment status was:  Recruiting
First Posted : October 8, 2015
Last Update Posted : November 17, 2015
Sponsor:
Information provided by (Responsible Party):
D-Pharm Ltd.

Brief Summary:

This study will test the experimental drug "THR-18" given together with the drug "tissue plasminogen activator" for the treatment of stroke. Tissue plasminogen activator is also called "tPA".

Strokes often result from blockade of blood supply caused by blood clots forming within the blood vessel feeding the brain. Such strokes are called "Ischemic strokes". Treatment of these strokes is aimed at breaking up the blood clot(s) and renewing the blood flow before further parts of the brain die. Breaking up the blood clot is possible with the drug tPA when it is injected into a vein shortly after the stroke starts. However, along with breaking up the blood clot, tPA sometimes causes adverse effects, for example, it may cause bleeding. THR-18, the drug tested in this study, is meant to reduce tPA's adverse effects without stopping tPA's breaking up of the blocking blood clot.

The aims of this study are to evaluate the safety of THR-18 in acute ischemic stroke patients who are treated in parallel with tPA, to measure tPA's effect on blood clot dissolution when this drug is given with and without THR-18, and to study the effects THR-18 may have on signals of brain damage as seen on brain computerized tomography (a type of brain x-ray) after treatment with tPA with and without THR-18. Patients will also be evaluated for their ability to perform daily activities after the stroke following tPA treatment with and without THR-18.

The evaluation of THR-18 in this study will be done in comparison to placebo. Placebo is a drug that looks exactly like THR-18 but has no activity. One dose of THR-18 will be tested, in 20 patients. In parallel, 20 other patients will receive placebo. In total, 40 patients are planned to participate in this study. The decision whether a patient will receive THR-18 or placebo will be based on chance (this procedure is called "randomization"). This clinical study will be conducted only at one hospital, in the Republic of Moldova. The patients will be in the hospital for at least 3 days after receiving the study treatment. Then, about 1 month later, they will be invited for a last follow-up visit.


Condition or disease Intervention/treatment Phase
Ischemic Stroke Drug: THR-18 Drug: Placebo Drug: Tissue Plasminogen Activator (tPA) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase II Study to Assess the Safety, Imaging, Pharmacodynamic and Clinical Outcomes of Acute Ischemic Stroke Subjects Treated With tPA and THR-18
Study Start Date : October 2015
Estimated Primary Completion Date : March 2016
Estimated Study Completion Date : April 2016

Arm Intervention/treatment
Active Comparator: THR-18
Single administration of intravenous THR-18 solution
Drug: THR-18
THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.

Drug: Tissue Plasminogen Activator (tPA)
tPA is a thrombolytic agent. tPA is not an investigational drug.

Placebo Comparator: Placebo
Single administration of intravenous THR-18 lookalike solution
Drug: Placebo
Placebo is a THR-18 lookalike, to be administered with tPA.

Drug: Tissue Plasminogen Activator (tPA)
tPA is a thrombolytic agent. tPA is not an investigational drug.




Primary Outcome Measures :
  1. physical examination [ Time Frame: 30 days after administration ]
  2. ASPECTS score [ Time Frame: 2 days after administration ]
  3. ECASS-II bleeding grades [ Time Frame: 2 days after administration ]
  4. Severity of cerebral edema per computerized tomography according to the IST-3 grades [ Time Frame: 2 days after administration ]
  5. Final infarct volume per computerized tomography [ Time Frame: 30 days after administration ]
  6. Neurological deficits per the NIH stroke scale [ Time Frame: 30 days after administration ]
  7. Functional capacity per the modified Rankin Score [ Time Frame: 30 days after administration ]
  8. Change in blood levels of matrix metalloproteinase 9 [ Time Frame: 3 days after administration ]
  9. heart rate [ Time Frame: 30 days after administration ]
  10. blood pressure [ Time Frame: 30 days after administartion ]
  11. electrocardiogram [ Time Frame: 30 days after administration ]
  12. persons with adverse events [ Time Frame: 30 days after administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 to 80 years, both inclusive.
  • Acute ischemic stroke, defined as an acute, focal, neurological deficit(s), secondary to an ischemic vascular event, which must include at baseline at least 1 of the following components as reflected by at least 1 point on items 9, 3 and 11 of the National Institutes of Health Stroke Scale (NIHSS), i.e. language dysfunction (aphasic disorder, excluding dysarthria), visual field defect (excluding monocular blindness), extinction and inattention.
  • NIHSS above 5 and below 18 for left and right hemisphere strokes.
  • Indication for the administration of intravenous tPA for acute stroke in accordance with tPA's authorized label for acute stroke.
  • Pre-stroke modified Rankin Scale score lower or equal to 2.
  • Ability to understand the requirements of the study and willing to provide written informed consent. In the event of incapacitated subjects, informed consent will be sought from a legally acceptable representative or by any other means as approved by the Ethics Committee.
  • No contraindication to i.v. administration of iodinated contrast agent

Exclusion Criteria:

  • Contraindications for tPA administration because of an increased risk of bleeding
  • Known hypersensitivity to tPA or to iodinated contrast agents.
  • Neurological deficit that has led to stupor or coma (NIHSS level of consciousness score above or equal to 2).
  • Stroke 90 days before screening/baseline assessments that is either confirmed or assumed to be in the same cerebral territory as is the current acute stroke.
  • Seizure any time between stroke symptoms onset and randomization.
  • Life expectancy below 1 month.
  • Serious illness, e.g. heart failure grade III or IV according to the New York Heart - Association functional classification, severe hepatic or renal failure.
  • Neurological or non-neurological disease that in the investigator's opinion may confound the assessment of the treatment's safety or biological effects.
  • Estimated creatinine clearance equal to or lower than 45 mL/min or dependency on renal dialysis.
  • Treatment of the qualifying stroke with intravenous heparin unless activated partial thromboplastin time prolongation is not more than 2 seconds above the upper limit of normal for local laboratory prior to study drug initiation.
  • Treatment of the qualifying stroke with a low molecular weight heparin or heparinoid.
  • Female of childbearing potential who is not willing to use adequate and effective birth control measures for the duration of the trial.
  • Positive urine pregnancy test at screening/baseline or lactating female.
  • Body weight (measured or estimated) above 100 kg.
  • Current drug or alcohol abuse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02572336


Contacts
Layout table for location contacts
Contact: Gilad Rosenberg, MD +972544474409 grosenberg@dpharm.com

Locations
Layout table for location information
Moldova, Republic of
Municipal Emergency Hospital Recruiting
Chisinau, Moldova, Republic of
Contact: Prof. Stanslav Groppa, MD, PhD         
Sponsors and Collaborators
D-Pharm Ltd.

Layout table for additonal information
Responsible Party: D-Pharm Ltd.
ClinicalTrials.gov Identifier: NCT02572336     History of Changes
Other Study ID Numbers: Ptcl-01462
First Posted: October 8, 2015    Key Record Dates
Last Update Posted: November 17, 2015
Last Verified: October 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Plasminogen
Tissue Plasminogen Activator
Stroke
Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action